Copeptin has been reported to be an excellent tool for AMI rapid rule-out when combined with cTn evaluation in patients with potential AMI, as well as for risk stratification and outcome prediction in patients with AMI, HF, and stroke. The gene discussed is AVP; the disease is stroke disorder.